Results: The frequency of the coughing decreased significantly 12 months later (the last 4 months) as compared to the first 4 months in both groups. Concerning the wheeze, the significant change was also examined in both groups. As for the frequency of the b2-receptor agonist inhalation consumption, the significant decrease was observed in group A and B. The meaningful change of the peripheral blood eosinophile count was not watched in group A and B. The serum IgE value decreased 12 months later in the subgroup of group A, who showed the decreased frequency of symptoms, whereas such a meaningful decrease was never recognized in group B. PLK-EK likely restrains an increase of serum IgE value. Conclusions: Pranlukast-EK modulates IgE production and eosinophile count in patients with the mild and moderate type of bronchial asthma, and has action to improve wheeze expression clinically.
Background: Short acting beta-2 agonists (SABA) inhalation is commonly used in bronchodilatatory test, which is still an important research tool in the diagnosis of respiratory diseases with bronchial obstruction. Bronchodilatatory effect of SABA depends primarily on the degree of patency of the airway, the type and dose of SABA, as well as the type of inhaler and inhalation technique. The aim of the study was to evaluate the spirometric effectiveness of 2 different methods of salbutamol nebulization in asthmatic children. Methods: The study group included 132 children aged 6 to 18 years (mean: 11.7), 91 (69%) boys and 41 (31%) girls with partly controlled asthma treated in the Allergy or Pulmonology Outpatient Clinics in Children's University Hospital in Lublin. The study was randomized and single blind design. Patients were randomly assigned to one of 2 groups. The first group used 2.2 mg of salbutamol (mean calculated dose) in the breath-actuated nebulizer (BAN) (Marine, Medbryt, Poland), while the second one-5 mg salbutamol (constans dose) in the constant-output nebulizer (CON) (Porta-Neb, MEDIC-AID, UK). Flow-volume curve (dynamic spirometry) was measured before and 20 minuts. after drug nebulization (bronchodilatatory test). FEV1 (expiratory volume in first second) and FEF25-75 (forced expiratory flow at 25 to 75% of forced vital capacity) values were analyzed. The change in FEV1 and FEF25-75 after treatment with respect to baseline was calculated. Results: The mean baseline value of FEV1 was 67.4% in BAN and 70.5% in CON group and there was no statistical difference between these groups. The significant improvement of measured ventilatory parameters was observed. There was the significant difference in the bronchodilator response to salbutamol between 2 methods of nebulization. The value of FEV1 increased at 16.2% in BAN group and at 12.6% in CON group (P ¼ 0,026). The value of FEF25-75 increased in both groups at 37.7% and 32.7% respectively and there was no statistical difference between these groups. Conclusions: We observed greater bronchodilatatory effect of salbutamol inhaled via breath-actuated nebulizer while delivering a double lower dose. 2. Bronchodilatatory test using nebulized salbutamol in breath-actuated nebulizer should be recommended for children. Background: Several practical issues dealing with the exact application of allergen immunotherapy (AIT) among European and US allergists are not well known. Guidelines on AIT give recommendations and suggestions for only some of them. We present this unique survey with worldwide response. Methods: The AAAAI immunotherapy committee conducted a web-based practice patterns survey (program: Survey Monkey) among all members in&outside US on dosing, dose-adjustment after missed doses and duration of AIT. Results: 1201 Returned questionnaires (almost 25% response rate). 21% were non-US-Canada members. Maintenance doses in USCan are (mean/ median): Dermatophagoides farinae (Df) combined with Dermatophagoides pteronyssinus (Dpt): 2155/1000AU; Df solo 2484/1000AU. Dpt when combined with Df 1937/1000AU; Dpt solo: 2183/1000AU.Cat 3224/2000BAU. Grass 11,410/4000BAU. 57-65% of the dosing falls within the recommended Practice Parameters recommended ranges. Non-USCan allergists expressed maintenance doses in many different units making analysis impossible. Doseadjustment after missed doses is based on 'time elapsed since the last applied dose' by 77% of USCan and 58% of non-USCan allergists and on 'time since missed scheduled dose' by the rest. Doses are adjusted when a patient comes in more than 14 d/5 wk after the last administration at build-up/maintenance by both USCan and non-USCan colleagues. The mostly followed dose-adjustment schedules after 1, 2, 3 missed doses are: Build-up: repeat last dose, reduce by one dose, reduce by 2 doses; maintenance: reduce by one dose, reduce by 2 doses, reduce by 3 doses. 26% uses a different approach reducing doses by a certain percentage or volume. AIT is restarted after a gap in buildup of .30 days and of .12 weeks during maintenance in both groups (median). Outside USCan AIT is prescribed for 3 years (Median). However, 75% of USCan allergists prescribes AIT for 5 years. Main reasons why to
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